FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1578659217> ?p ?o ?g. }

• W1578659217 endingPage "638" @default.
• W1578659217 startingPage "629" @default.
• W1578659217 abstract "ONO-5334 (Ono Pharmaceutical Co., Ltd., Osaka, Japan) inhibits cathepsin K and has been shown to increase areal bone mineral density (BMD) at the hip and spine in postmenopausal osteoporosis. Quantitative computed tomography (QCT) allows the study of the cortical and trabecular bone separately and provides structural information such as cortical thickness. We investigated the impact of 2 years of cathepsin K inhibition on these different bone compartments with ONO-5334. The clinical study was a randomized, double-blind, placebo, and active controlled parallel group study conducted in 13 centers in six European countries. The original study period of 12 months was extended by another 12 months. A total of 147 subjects (age 55–75 years) of the QCT substudy who participated in the extension period were included. Subjects had been randomized into one of five treatment arms: placebo; ONO-5334 50 mg twice per day (BID); ONO-5334 100 mg once daily (QD); ONO-5334 300 mg QD; or alendronate 70 mg once weekly (QW). QCT was obtained to evaluate bone structure at the lumbar spine and proximal femur. After 24 months ONO-5334 showed statistically significant increases versus placebo for integral, trabecular, and cortical BMD at the spine and the hip (for ONO-5334 300 mg QD, BMD increases were 10.5%, 7.1%, and 13.4% for integral, cortical, and trabecular BMD at the spine, respectively, and 6.2%, 3.4%, and 14.6% for integral, cortical, and trabecular total femur BMD, respectively). Changes in cortical and trabecular BMD in the spine and hip were similar for alendronate as for ONO-5334. Integral volume did not demonstrate statistically significant changes under ONO-5334 treatment, thus there was no evidence of periosteal apposition, neither at the spine nor at the femur. Cortical thickness changes were not statistically significant for ONO-5334 in the spine and hip, with exception of a 2.1% increase after month 24 in the intertrochanter for ONO-5334 300 mg QD. Over 2 years ONO-5334 showed a statistically significant and persistent increase of trabecular and integral BMD at the spine and the hip. Cortical BMD also progressively increased but at a lower rate. Changes in bone size and of periosteal apposition were not observed. © 2014 American Society for Bone and Mineral Research." @default.
• W1578659217 created "2016-06-24" @default.
• W1578659217 creator A5007167127 @default.
• W1578659217 creator A5024183255 @default.
• W1578659217 creator A5024548519 @default.
• W1578659217 creator A5025603231 @default.
• W1578659217 creator A5034530253 @default.
• W1578659217 creator A5042012204 @default.
• W1578659217 creator A5064307236 @default.
• W1578659217 creator A5091603719 @default.
• W1578659217 date "2014-02-19" @default.
• W1578659217 modified "2023-10-10" @default.
• W1578659217 title "The Effect of the Cathepsin K Inhibitor ONO-5334 on Trabecular and Cortical Bone in Postmenopausal Osteoporosis: The OCEAN Study" @default.
• W1578659217 cites W1967356192 @default.
• W1578659217 cites W1983634909 @default.
• W1578659217 cites W1988599801 @default.
• W1578659217 cites W1990771263 @default.
• W1578659217 cites W1993991718 @default.
• W1578659217 cites W2000411736 @default.
• W1578659217 cites W2010260213 @default.
• W1578659217 cites W2010263562 @default.
• W1578659217 cites W2016562615 @default.
• W1578659217 cites W2043232149 @default.
• W1578659217 cites W2058616210 @default.
• W1578659217 cites W2080868401 @default.
• W1578659217 cites W2084806705 @default.
• W1578659217 cites W2091713669 @default.
• W1578659217 cites W2108824264 @default.
• W1578659217 cites W2109269643 @default.
• W1578659217 doi "https://doi.org/10.1002/jbmr.2080" @default.
• W1578659217 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24038152" @default.
• W1578659217 hasPublicationYear "2014" @default.
• W1578659217 type Work @default.
• W1578659217 sameAs 1578659217 @default.
• W1578659217 citedByCount "38" @default.
• W1578659217 countsByYear W15786592172014 @default.
• W1578659217 countsByYear W15786592172015 @default.
• W1578659217 countsByYear W15786592172016 @default.
• W1578659217 countsByYear W15786592172017 @default.
• W1578659217 countsByYear W15786592172018 @default.
• W1578659217 countsByYear W15786592172019 @default.
• W1578659217 countsByYear W15786592172020 @default.
• W1578659217 countsByYear W15786592172021 @default.
• W1578659217 countsByYear W15786592172022 @default.
• W1578659217 crossrefType "journal-article" @default.
• W1578659217 hasAuthorship W1578659217A5007167127 @default.
• W1578659217 hasAuthorship W1578659217A5024183255 @default.
• W1578659217 hasAuthorship W1578659217A5024548519 @default.
• W1578659217 hasAuthorship W1578659217A5025603231 @default.
• W1578659217 hasAuthorship W1578659217A5034530253 @default.
• W1578659217 hasAuthorship W1578659217A5042012204 @default.
• W1578659217 hasAuthorship W1578659217A5064307236 @default.
• W1578659217 hasAuthorship W1578659217A5091603719 @default.
• W1578659217 hasBestOaLocation W15786592171 @default.
• W1578659217 hasConcept C105702510 @default.
• W1578659217 hasConcept C126322002 @default.
• W1578659217 hasConcept C126894567 @default.
• W1578659217 hasConcept C134018914 @default.
• W1578659217 hasConcept C141071460 @default.
• W1578659217 hasConcept C142724271 @default.
• W1578659217 hasConcept C204787440 @default.
• W1578659217 hasConcept C27081682 @default.
• W1578659217 hasConcept C2776541429 @default.
• W1578659217 hasConcept C2776886416 @default.
• W1578659217 hasConcept C2777425516 @default.
• W1578659217 hasConcept C2780554211 @default.
• W1578659217 hasConcept C2781451080 @default.
• W1578659217 hasConcept C71924100 @default.
• W1578659217 hasConceptScore W1578659217C105702510 @default.
• W1578659217 hasConceptScore W1578659217C126322002 @default.
• W1578659217 hasConceptScore W1578659217C126894567 @default.
• W1578659217 hasConceptScore W1578659217C134018914 @default.
• W1578659217 hasConceptScore W1578659217C141071460 @default.
• W1578659217 hasConceptScore W1578659217C142724271 @default.
• W1578659217 hasConceptScore W1578659217C204787440 @default.
• W1578659217 hasConceptScore W1578659217C27081682 @default.
• W1578659217 hasConceptScore W1578659217C2776541429 @default.
• W1578659217 hasConceptScore W1578659217C2776886416 @default.
• W1578659217 hasConceptScore W1578659217C2777425516 @default.
• W1578659217 hasConceptScore W1578659217C2780554211 @default.
• W1578659217 hasConceptScore W1578659217C2781451080 @default.
• W1578659217 hasConceptScore W1578659217C71924100 @default.
• W1578659217 hasIssue "3" @default.
• W1578659217 hasLocation W15786592171 @default.
• W1578659217 hasLocation W15786592172 @default.
• W1578659217 hasOpenAccess W1578659217 @default.
• W1578659217 hasPrimaryLocation W15786592171 @default.
• W1578659217 hasRelatedWork W1472547345 @default.
• W1578659217 hasRelatedWork W1988918570 @default.
• W1578659217 hasRelatedWork W2093936017 @default.
• W1578659217 hasRelatedWork W2152538074 @default.
• W1578659217 hasRelatedWork W2356113455 @default.
• W1578659217 hasRelatedWork W2417780178 @default.
• W1578659217 hasRelatedWork W2546719421 @default.
• W1578659217 hasRelatedWork W2671531964 @default.
• W1578659217 hasRelatedWork W3188480364 @default.
• W1578659217 hasRelatedWork W3214995654 @default.
• W1578659217 hasVolume "29" @default.

• next